Toxicity and Antimicrobial Activity of a Hydrocolloid Dressing Containing Silver Particles in an ex vivo Model of Cutaneous Infection

Skin Pharmacology and Physiology

Volumn 17, Issue 1, 2004, Pages 31-36

  Schaller, M ^a   Laude, J ^a   Bodewaldt, H ^c   Hamm, G ^b   Korting, H C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c NONE   (Germany)

Author keywords

Candida albicans; Methicillin resistant Staphylococcus aureus; Occlusive dressing; Reconstituted human epithelium; Silver; Wound

Indexed keywords

COMFEEL; LACTATE DEHYDROGENASE; SILVER;

ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CELL STRUCTURE; CELL ULTRASTRUCTURE; CELL VACUOLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SPECIFICITY; EDEMA; ELECTRON MICROSCOPY; ENZYME RELEASE; EPITHELIUM; EPITHELIUM CELL; HUMAN; HUMAN CELL; HYDROCOLLOID; KERATINOCYTE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTIVE CLOTHING; SKIN INFECTION; WOUND DRESSING;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BANDAGES, HYDROCOLLOID; CANDIDA ALBICANS; COLLOIDS; EPITHELIUM; HUMANS; KERATINOCYTES; METHICILLIN RESISTANCE; MODELS, BIOLOGICAL; OCCLUSIVE DRESSINGS; RISK ASSESSMENT; SILVER; STAPHYLOCOCCUS AUREUS; WOUND INFECTION;

EID: 1342301601     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074060     Document Type: Article

References (31)

1. Matsukawa M, Kunishima Y, Takahashi S, Takeyama K, Tsukamoto T: Staphylococcus aureus bacteriuria and surgical site infections by methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2001;17:327-329, discussion 329-330.
2. Giandoni MB, Grabski WJ: Cutaneous candidiasis as a cause of delayed surgical wound healing. J Am Acad Dermatol 1994;30:981-984.
3. Nishijima S, Kurokawa I: Antimicrobial resistance of Staphylococcus aureus isolated from skin infections. Int J Antimicrob Agents 2002;19:241-243.
4. Nishijima S, Namura S, Mitsuya K, Asada Y: The incidence of isolation of methicillin-resistant Staphylococcus aureus (MRSA) strains from skin infections during the past three years (1989-1991). J Dermatol 1993;20:193-197.
5. White TC, Holleman S, Dy F, Mirels LF, Stevens DA: Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002;46:1704-1713.
6. Yin HQ, Langford R, Burrell RE: Comparative evaluation of the antimicrobial activity of ACTICOAT antimicrobial barrier dressing. J Burn Care Rehabil 1999;20:195-200.
7. Mertz PM, Oliveira-Gandia MF, Davis SC: The evaluation of a cadexomer iodine wound dressing on methicillin resistant Staphylococcus aureus (MRSA) in acute wounds. Dermatol Surg 1999;25:89-93.
8. National Committee for Clinical Laboratory Standards (NCCLS): Approved Standards M7-A5, M100-S10: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Wayne, NCCLS, 2000.
9. Gillum AM, Tsay EY, Kirsch DR: Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 1984;198:179-182.
10. Bonowitz A, Schaller M, Laude J, Reimer K, Korting HC: Comparative therapeutic and toxic effects of different povidone iodine (PVPI) formulations in a model of oral candidosis based on in vitro reconstituted epithelium. J Drug Target 2001;9:75-83.
11. Rupniak HT, Rowlatt C, Lane EB, Steele JG, Trejdosiewicz LK, Laskiewicz B, Povey S, Hill BT: Characteristics of four new human cell lines derived from squamous cell carcinomas of the head and neck. J Natl Cancer Inst 1985;75:621-635.
12. Wróblewski F, John SL: Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med 1955;90:210-213.
13. Hutchinson JJ: Infection under occlusion. Ostomy Wound Manage 1994;40:28-30, 32-23.
14. Hutchinson JJ, Lawrence JC: Wound infection under occlusive dressings. J Hosp Infect 1991;17:83-94.
15. Hutchinson JJ, McGuckin M: Occlusive dressings: A microbiologic and clinical review. Am J Infect Control 1990;18:257-268.
16. Wright JB, Lam K, Burrell RE: Wound management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment. Am J Infect Control 1998;26:572-577.
17. Wright JB, Lam K, Buret AG, Olson ME, Burrell RE: Early healing events in a porcine model of contaminated wounds: Effects of nanocrystalline silver on matrix metalloproteinases, cell apoptosis, and healing. Wound Repair Regen 2002;10:141-151.
18. Wright JB, Lam K, Hansen D, Burrell RE: Efficacy of topical silver against fungal burn wound pathogens. Am J Infect Control 1999;27:344-350.
19. Chung JY, Herbert ME: Myth: Silver sulfadiazine is the best treatment for minor burns. West J Med 2001;175:205-206.
20. Schaller M, Wurm R, Korting HC: Direct evidence for uptake of intact liposomes encapsulating silver sulfadiazine by cultured human keratinocytes based on combined transmission electron microscopy and X-ray microanalysis. Antimicrob Agents Chemother 1997;41:717-719.
21. Schaller M, Korting HC, Schmid MH: Interaction of cultured human keratinocytes with liposomes encapsulating silver sulphadiazine: Proof of the uptake of intact vesicles. Br J Dermatol 1996;134:445-450.
22. Demling RH, Leslie DeSanti MD: The rate of re-epithelialization across meshed skin grafts is increased with exposure to silver. Burns 2002;28:264-266.
23. Innes ME, Umraw N, Fish JS, Gomez M, Cartotto RC: The use of silver coated dressings on donor site wounds: A prospective, controlled matched pair study. Burns 2001;27:621-627.
24. de Brugerolle de F, Picarles V, Chibout S, Kolopp M, Medina J, Burtin P, Ebelin ME, Osborne S, Mayer FK, Spake A, Rosdy M, De Wever B, Ettlin RA, Cordier A: Predictivity of an in vitro model for acute and chronic skin irritation (SkinEthic) applied to the testing of topical vehicles. Cell Biol Toxicol 1999;15:121-135.
25. Tredget EE, Shankowsky HA, Groeneveld A, Burrell R: A matched-pair, randomized study evaluating the efficacy and safety of Acticoat silver-coated dressing for the treatment of burn wounds. J Burn Care Rehabil 1998;19:531-537.
26. Rogers KS: Protein fluorescence and inactivation of lactate dehydrogenases during treatment with silver. Enzymologia 1969;37:174-178.
27. Schaller M, Korting HC, Schafer W, Bastert J, Chen W, Hube B: Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis. Mol Microbiol 1999;34:169-180.
28. Schaller M, Schafer W, Korting HC, Hube B: Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol 1998;29:605-615.
29. Gilchrist B, Reed C: The bacteriology of chronic venous ulcers treated with occlusive hydrocolloid dressings. Br J Dermatol 1989;121:337-344.
30. Katz S, McGinley K, Leyden JJ: Semipermeable occlusive dressings: Effects on growth of pathogenic bacteria and reepithelialization of superficial wounds. Arch Dermatol 1986;122:58-62.
31. Varghese MC, Balin AK, Carter DM, Caldwell D: Local environment of chronic wounds under synthetic dressings. Arch Dermatol 1986;122:52-57.